Witnessing the stock’s movement on the chart, on Wednesday, Prelude Therapeutics Inc (NASDAQ: PRLD) set off with pace as it heaved 7.14% to $1.05, before settling in for the price of $0.98 at the close. Taking a more long-term approach, PRLD posted a 52-week range of $0.93-$6.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 0.00%. Meanwhile, its Annual Earning per share during the time was -43.14%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 11.63%. This publicly-traded company’s shares outstanding now amounts to $42.06 million, simultaneously with a float of $22.37 million. The organization now has a market capitalization sitting at $61.92 million. At the time of writing, stock’s 50-day Moving Average stood at $1.5996, while the 200-day Moving Average is $3.7459.
Prelude Therapeutics Inc (PRLD) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Prelude Therapeutics Inc’s current insider ownership accounts for 59.35%, in contrast to 35.27% institutional ownership.
Prelude Therapeutics Inc (PRLD) Earnings and Revenue Records
Prelude Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 11.63% and is forecasted to reach -1.48 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 30.10% through the next 5 years, which can be compared against the -43.14% growth it accomplished over the previous five years trading on the market.
Prelude Therapeutics Inc (NASDAQ: PRLD) Trading Performance Indicators
Let’s observe the current performance indicators for Prelude Therapeutics Inc (PRLD). It’s Quick Ratio in the last reported quarter now stands at 7.04. The Stock has managed to achieve an average true range (ATR) of 0.10. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 20.64.
In the same vein, PRLD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.90, a figure that is expected to reach -0.47 in the next quarter, and analysts are predicting that it will be -1.48 at the market close of one year from today.
Technical Analysis of Prelude Therapeutics Inc (PRLD)
Going through the that latest performance of [Prelude Therapeutics Inc, PRLD]. Its last 5-days volume of 0.37 million indicated improvement to the volume of 0.17 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 41.02% While, its Average True Range was 0.0769.
Raw Stochastic average of Prelude Therapeutics Inc (PRLD) in the period of the previous 100 days is set at 2.03%, which indicates a major fall in contrast to 33.08% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 68.17% that was lower than 144.55% volatility it exhibited in the past 100-days period.
